Clinical Director, Deputy Scientific Director, Branch Chief, Senior Investigator
NIDA/NIAAA, NIH, Maryland
Dr. Lorenzo Leggio is a physician-scientist, whose clinical work and clinical research have been primarily focused on the treatment of alcohol and substance use disorders and on the medical consequences of alcohol use disorder, especially alcohol-associated liver and cardiovascular diseases. Dr. Leggio, together with his team have conducted research on medication development, on the role of the microbiome-gut-liver-brain axis, on the role of neuroendocrine pathways in addiction, via human laboratory studies and clinical trials as well as via translational and reverse translational experimental medicine approaches in animal models. Dr. Leggio received his M.D. and Ph.D. from the Catholic University of Rome and Agostino Gemelli Hospital, where he also completed residency and received Board Certification in Internal Medicine. He was a postdoctoral research associate in Psychiatry and Human Behavior at Brown University, Providence, RI, where he joined the core faculty of the Center for Alcohol and Addiction Studies as Assistant Professor in 2010. As PI at Brown University, he received extramural research funding from NIAAA and NIDA, as well as from several foundations. Dr. Leggio was recruited as a Tenure-Track Clinical Investigator (joint NIAAA/NIDA) at the NIH IRP, where he also serves as a NIH Senior Attending Medical Staff. Dr. Leggio currently serves as the NIDA Clinical Director and Deputy Scientific Director. He was the founder in 2012 and current Chief of the Clinical Psychoneuroendocrinology and Neuropsychopharmacology Section, a joint NIDA and NIAAA laboratory. He was the founder in 2020 and current Chief of the NIDA IRP Translational Addiction Medicine Branch. Dr. Leggio was also the founder and serves as the Director of the NIDA IRP Translational Analytical Core. He further serves as Senior Medical Advisor to the NIAAA Director. He is also Adjunct Professor at Brown University, Johns Hopkins University and Georgetown University. In 2022, Dr. Leggio was elected Fellow of the American College of Neuropsychopharmacology. Among other honors, Dr. Leggio received the 2018 Eva King Killam Award from the American College of Neuropsychopharmacology, the 2020 Jacob P. Waletzky Award from the Society for Neuroscience, the 2023 Ward & Ryan Donovan Lectureship Award from the American College of Medical Toxicology, and the 2024 Max Glatt Memorial Lectureship Award from the U.K. Medical Council on Alcohol. Dr. Leggio was also presented as one of the twelve recipients of the 2023 Arthur S. Flemming Award (Social Science, Clinical Trials, and Translational Research category) for his groundbreaking research in addiction science.
Disclosure information not submitted.
Spironolactone in Alcohol Addiction: A Translational Approach
Friday, October 18, 2024
8:50 AM – 9:10 AM ET
